News
Resources
Blog
Sites
New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system
By Gabby Migliara | October 14, 2021
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending –...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country
By Nicole Longo | July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
Getting the 340B program back on track in 2021
By Nicole Longo | March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
By Nicole Longo | December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
By Nicole Longo | October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...
Read More
Survey found insurance premiums grew faster than inflation in 2020
By Gabby Migliara | October 20, 2020
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than both the rate...
Read More
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
New GAO report: Some hospitals participating in 340B may not be eligible for the program
By Nicole Longo | January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others
By Holly Campbell | January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
By Holly Campbell | December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
